Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
17 hedge funds and large institutions have $12.7M invested in Timber Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
25% more capital invested
Capital invested by funds: $10.2M → $12.7M (+$2.53M)
21% more funds holding
Funds holding: 14 → 17 (+3)
6.32% less ownership
Funds ownership: 83% → 76.68% (-6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$173K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.1K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$41.5K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$41.5K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$20.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$502K |
| 2 |
SCM
Sio Capital Management
New York
|
-$381K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$265K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$30K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$4K |
TMBR Hedge Fund Activity: Q1 2017 in Review
17 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q1 2017, worth a combined $12.7M — up 25% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TMBR positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $173K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $502K sold.
- 17 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q1 2017, up from 14 in Q4 2016.
- Funds reported $12.7M of Timber Pharmaceuticals, Inc. stock for Q1 2017, up 25% quarter-over-quarter.
- 7 funds opened new Timber Pharmaceuticals, Inc. positions in Q1 2017 and 4 closed out, a net change of +3 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q1 2017 was Baker Bros. Advisors, an estimated $173K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q1 2017 was EcoR1 Capital, an estimated $502K sold.
Based on aggregated 13F filings for Q1 2017.